New MGA Analysis of Biosimilar Coverage in Commercial Medical Benefit
New MGA Analysis of Biosimilar Coverage in Commercial Medical Benefit A new MGA white paper from CEO Alex Brill and Principal Christy Robinson shows a positive outlook for biosimilar coverage in the commercial medical benefit. While patients and physicians play a role...
Updated MGA Report Presents Biosimilar Market Opportunities in Ophthalmology
Updated MGA Report Presents Biosimilar Market Opportunities in Ophthalmology MGA releases an updated report, “Biosimilar Market Opportunities in Ophthalmology.” Authored by founder and CEO Alex Brill, the report examines the economics of biologic drugs for...
New MGA Report Presents Biosimilar Market Opportunities in Ophthalmology
New MGA Report Presents Biosimilar Market Opportunities in Ophthalmology MGA releases a new report, “Biosimilar Market Opportunities in Ophthalmology.” Authored by founder and CEO Alex Brill, the report examines current trends and economics in the ophthalmology...- Health Care Workforce Shortages: An Updated Look
- New MGA Analysis of the Adalimumab Biosimilars Market in the United States
- MGA’s Alex Brill on CNBC’s Squawk Box Discussing the Recent Tax Policy Proposal
- Bipartisan Senate Bill Aims to Curb Drug Patent Abuse
- Humira Rivals Set to Try to Drive Down Cost of Blockbuster Drug
- New Report from MGA Examines the One-Year Cost Savings Lost Due to Patent Thickets
- New MGA Analysis of Biosimilar Coverage in Commercial Medical Benefit
- Narrow House GOP Victory Should Point Toward Policy Development Agenda
- Don’t Let Pandemic Fatigue Inhibit Pandemic Preparedness
- American Renewal: A Simpler, More Responsible, and Pro-Growth Tax System
